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Abstract
Background: Transcatheter left atrial appendage occlusion (LAAO) is a promising therapy for stroke prophylaxis in
non-valvular atrial fibrillation (NVAF) but its cost-effectiveness remains understudied. This study evaluated the cost-
effectiveness of LAAO for stroke prophylaxis in NVAF.
Methods: A Markov decision analytic model was used to compare the cost-effectiveness of LAAO with 7
pharmacological strategies: aspirin alone, clopidogrel plus aspirin, warfarin, dabigatran 110 mg, dabigatran 150 mg,
apixaban, and rivaroxaban. Outcome measures included quality-adjusted life years (QALYs), lifetime costs and
incremental cost-effectiveness ratios (ICERs). Base-case data were derived from ACTIVE, RE-LY, ARISTOTLE, ROCKET-AF,
PROTECT-AF and PREVAIL trials. One-way sensitivity analysis varied by CHADS2 score, HAS-BLED score, time horizons,
and LAAO costs; and probabilistic sensitivity analysis using 10,000 Monte Carlo simulations was conducted to assess
parameter uncertainty.
Results: LAAO was considered cost-effective compared with aspirin, clopidogrel plus aspirin, and warfarin, with ICER of
US$5,115, $2,447, and $6,298 per QALY gained, respectively. LAAO was dominant (i.e. less costly but more effective)
compared to other strategies. Sensitivity analysis demonstrated favorable ICERs of LAAO against other strategies in
varied CHADS2 score, HAS-BLED score, time horizons (5 to 15 years) and LAAO costs. LAAO was cost-effective in
86.24 % of 10,000 simulations using a threshold of US$50,000/QALY.
Conclusions: Transcatheter LAAO is cost-effective for prevention of stroke in NVAF compared with 7
pharmacological strategies.
Condensed abstract: The transcatheter left atrial appendage occlusion (LAAO) is considered cost-effective against the
standard 7 oral pharmacological strategies including acetylsalicylic acid (ASA) alone, clopidogrel plus ASA, warfarin,
dabigatran 110 mg, dabigatran 150 mg, apixaban, and rivaroxaban for stroke prophylaxis in non-valvular atrial
fibrillation management.
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Background
Atrial fibrillation (AF) is associated with 4–5 fold in-
crease risk for thromboembolic stroke [1]. Oral anticoa-
gulation therapy with warfarin is the standard therapy
for stroke prevention, but is difficult to maintain within
the narrow therapeutic range and is under-prescribed in
clinical practice. Potential alternatives to warfarin in-
clude anti-platelet therapy [2], novel oral anticoagulants
(NOACs) such as direct thrombin or factor Xa inhibitors
[3, 4] and exclusion of the left atrial appendage (LAA) as
a major embolic source [5, 6]. The randomized-
controlled WATCHMAN Left Atrial Appendage System
for Embolic Protection in Patients with Atrial Fibrilla-
tion (PROTECT-AF) trial [5] demonstrated that device
occlusion of the LAA orifice by the WATCHMAN
device (Boston Scientific, Natick, MA, USA) was non-
inferior to warfarin for the prevention of thrombo-
embolic events in NVAF patients. The cost of this device
ranges from US$5,770 to US$10,000 depending on the
country.
According to recent published economic evaluation
studies of LAA compared with warfarin or NOACs, the
results indicated that LAA was a cost-effective alterna-
tive for stroke prevention in AF patients [7, 8]. However,
comprehensive comparison with LAA and each oral
anticoagulant should be evaluated to demonstrate sig-
nificant outcomes. This study estimated the lifetime
cost-effectiveness of transcatheter left atrial appendage
occlusion (LAAO) for stroke prophylaxis in a hypothet-
ical cohort of 65-year-old patients with non-valvular AF
as compared to other pharmacological strategies.
Methods
Decision analytical model
A Markov decision analytic model was used to perform
a cost-effectiveness analysis from a US healthcare pro-
vider perspective expressed in US dollars. The model
was developed using TreeAge Pro Suite 2014 software
(TreeAge Software, Inc., Williamstown, MA) for evaluat-
ing the long-term costs and effectiveness of treatment
strategies for stroke prevention. Outcome measures in-
cluded quality-adjusted life years (QALYs), lifetime costs
and incremental cost-effectiveness ratios (ICERs). All
costs and QALYs were discounted at an annual rate of
3 %. The ICERs of < US$50,000 per QALY was consid-
ered cost-effective [9].
Model
The model of patients wth AF for stroke prevention
was adapted from literature and cardiology consultation
[8, 10]. A cohort of 65-year-old patients with non-valvular
AF without contraindication to anti-thrombotic therapies
was simulated moving between different health states in
each Markov cycle of 1 year. The time horizon was
lifetime (85 years old). Health states in the model included
patient in AF without event, with event before, ischemic
stroke (no residual, mild moderate to severe, fatal), transi-
ent ischemic attack (TIA), hemorrhage [minor, major,
intracranial hemorrhage (ICH), fatal], myocardial infarc-
tion (MI), death from vascular cause, and death from all
causes. Seven different pharmacological strategies for
stroke prevention including acetylsalicyclic acid (ASA)
alone (75 to 100 mg), clopidogrel (75 mg) plus ASA,
warfarin, dabigatran 110 mg, dabigatran 150 mg, apixa-
ban (5 mg) and rivaroxaban (20 mg) were compared
with LAAO. After LAAO, we assumed patients were
treated with warfarin for 45 days followed by clopido-
grel plus ASA for 180 days, and then lifelong ASA in
our study model as in the WATCHMAN trial. There
are studies such as the ASA Plavix Feasibility Study
with Watchman Left Atrial Appendage Closure Technology
(ASAP) study, which used antiplatelet therapy alone after
LAAO [5, 11, 12].
Model parameters
Base-case values for analytic model were derived from
published randomized studies including Atrial Fibrillation
Clopidogrel Trial with Irbesartan for Prevention of
Vascular Events (ACTIVE), Randomized Evaluation of
Long-Term Anticoagulation Therapy (RE-LY), Apixaban
for Reduction in Stroke and Other Throm-boembolic
Events in Atrial Fibrillation (ARISTOTLE), Rivaroxaban
Once Daily Oral Direct Factor Xa Inhibition Compared
with Vitamin K Antagonism for Prevention of Stroke and
Embolism Trial in Atrial Fibrillation (ROCKET-AF),
Watchman Left Atrial Appendage System for Embolic Pro-
tection in Patients With Atrial Fibrillation (PROTECT-AF),
and Prospective Randomized Evaluation of the WATCH-
MAN LAA Closure Device In Patients with Atrial Fibrilla-
tion Versus Long Term Warfarin Therapy (PREVAIL) trials
[2–5, 13, 14]. Table 1 summarized the clinical inputs and
data sources used in the base-case analysis. Warfarin event
rates were pooled warfarin events from RE-LY, ROCKET-
AF, and ARISTOTLE trails [3, 4, 13].
Ischemic stroke
The annual ischemic stroke rates were 2 · 8 %, 1 · 9 %,
1 · 21 %, 1 · 34 %, 0 · 92 %, 0 · 97 %, 1 · 34 % and 0 · 84 %
for ASA alone, clopidogrel plus ASA, warfarin, dabiga-
tran 110 mg, dabigatran 150 mg, apixaban, rivaroxa-
ban, and LAA occlusion, respectively [2–4, 13, 15–18].
Additionally, TIA accounted for 28 % [15, 17] of all
neurological ischemic events in this model. The an-
nual ischemic stroke rate of LAA occlusion was
pooled by PROTECT-AF and PREVAIL trails [5, 14].
Proportion of 4 sub-classifications of ischemic stroke
(no residual, mild, moderate to severe, fatal) varied ac-
cording to therapy [15, 17].
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Table 1 Clinical inputs for base-case value and ranges in decision analytic model
Variable Base-Case Range References
Stroke
Annual rate of ischemic stroke, %
Aspirin alone 2 · 80 2 · 80 4 · 50 [2, 18]
Clopidogrel plus aspirin 1 · 90 1 · 69 2 · 11 [2]
Warfarin 1 · 21 1 · 05 1 · 42 [3, 4, 13]
Dabigatran, 110 mg 1 · 34 1 · 31 1 · 55 [3, 15]
Dabigatran, 150 mg 0 · 92 0 · 75 1 · 09 [3, 15]
Apixaban 0 · 97 0 · 78 1 · 19 [13, 16]
Rivaroxaban 1 · 34 1 · 07 1 · 66 [4, 16]
LAA 0 · 84 0 · 40 1 · 10 [5, 14]
Ischemic stroke with clopidogrel plus aspirin or aspirin alone, %
Fatal (within 30 days) 17 · 90 10 · 10 17 · 90 [17]
Moderate to severe neurologic sequelae 30 · 00 30 · 00 41 · 70 [17]
Mild neurologic sequelae 41 · 00 34 · 80 41 · 00 [17]
No residual neurologic sequelae 11 · 00 11 · 00 13 · 30 [17]
Ischemic stroke with warfarin, dabigatran, apixaban, rivaroxaban
or LAA, %
Fatal (within 30 days) 8 · 20 5 · 50 10 · 90 [15, 17]
Moderate to severe neurologic sequelae 40 · 20 35 · 30 45 · 10 [15, 17]
Mild neurologic sequelae 42 · 50 37 · 60 47 · 40 [15, 17]
No residual neurologic sequelae 9 · 10 6 · 20 12 · 00 [15, 17]
Annual rate of TIA, % 28 · 00 25 · 00 33 · 00 [15, 17]
Hemorrhage
Annual rate of minor hemorrhage, %
Aspirin alone 1 · 40 1 · 27 1 · 53 [2]
Clopidogrel plus aspirin 3 · 50 2 · 58 4 · 42 [2]
Warfarin 18 · 63 11 · 40 25 · 80 [3, 4, 13]
Dabigatran, 110 mg 13 · 20 12 · 60 13 · 80 [3, 19]
Dabigatran, 150 mg 14 · 80 14 · 20 15 · 50 [3, 19]
Apixaban 18 · 10 17 · 54 19 · 35 [13]
Rivaroxaban 11 · 80 10 · 94 12 · 88 [4]
LAA (45 days warfarin followed by 180 days clopidogrel and aspirin
then lifetime aspirin after LAA)
4 · 28 3 · 70 4 · 86 Assumption
LAA (lifetime aspirin after LAA) 1 · 40 1 · 27 1 · 53 Assumption
Annual rate of major hemorrhage, %
Aspirin alone 1 · 00 0 · 68 1 · 32 [2]
Clopidogrel plus aspirin 1 · 50 1 · 35 1 · 65 [2]
Warfarin 3 · 32 3 · 09 3 · 57 [3, 4, 13]
Dabigatran, 110 mg 2 · 87 2 · 50 3 · 32 [3, 19]
Dabigatran, 150 mg 3 · 32 2 · 89 3 · 82 [3, 19]
Apixaban 2 · 13 1 · 85 2 · 47 [13]
Rivaroxaban 3 · 60 3 · 06 4 · 08 [4]
LAA (45 days warfarin followed by 180 days clopidogrel and aspirin
then lifetime aspirin after LAA)
1 · 54 1 · 30 1 · 77 Assumption
LAA (lifetime aspirin after LAA) 1 · 00 0 · 68 1 · 32 Assumption
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Table 1 Clinical inputs for base-case value and ranges in decision analytic model (Continued)
Annual rate of ICH, %
Aspirin alone 0 · 20 0 · 19 0 · 21 [2]
Clopidogrel plus aspirin 0 · 40 0 · 24 0 · 59 [2]
Warfarin 0 · 75 0 · 70 0 · 80 [3, 4, 13]
Dabigatran, 110 mg 0 · 23 0 · 14 0 · 32 [3, 15]
Dabigatran, 150 mg 0 · 30 0 · 20 0 · 40 [3, 15]
Apixaban 0 · 33 0 · 24 0 · 46 [13]
Rivaroxaban 0 · 50 0 · 33 0 · 65 [4]
LAA (45 days warfarin followed by 180 days clopidogrel and aspirin
then lifetime aspirin after LAA)
0 · 37 0 · 27 0 · 47 Assumption
LAA (lifetime aspirin after LAA) 0 · 20 0 · 19 0 · 21 Assumption
Annual rate of major hemorrhage as fatal, %
Aspirin alone 0 · 20 0 · 14 0 · 26 [2]
Clopidogrel plus aspirin 0 · 30 0 · 19 0 · 51 [2]
Warfarin 0 · 90 0 · 50 1 · 80 [3, 4, 13]
Dabigatran, 110 mg 1 · 22 1 · 08 1 · 36 [3]
Dabigatran, 150 mg 1 · 45 1 · 33 1 · 56 [3]
Apixaban 0 · 37 0 · 30 0 · 42 [13]
Rivaroxaban 0 · 20 0 · 16 0 · 40 [4]
LAA (45 days warfarin followed by 180 days clopidogrel and aspirin
then lifetime aspirin after LAA)
0 · 45 0 · 38 0 · 51 Assumption
LAA (lifetime aspirin after LAA) 0 · 20 0 · 14 0 · 26 Assumption
Myocardial infarction
Annual rate of MI, %
Aspirin alone 0 · 90 0 · 77 1 · 03 [2]
Clopidogrel plus aspirin 0 · 70 0 · 53 0 · 93 [2]
Warfarin 0 · 78 0 · 61 1 · 12 [3, 4, 13]
Dabigatran, 110 mg 0 · 82 0 · 61 1 · 12 [3, 19]
Dabigatran, 150 mg 0 · 81 0 · 60 1 · 09 [3, 19]
Apixaban 0 · 53 0 · 40 0 · 71 [13]
Rivaroxaban 0 · 91 0 · 71 1 · 19 [4]
LAA (45 days warfarin followed by 180 days clopidogrel and aspirin
then lifetime aspirin after LAA)
0 · 76 0 · 57 1 · 00 Assumption
LAA (lifetime aspirin after LAA) 0 · 90 0 · 77 1 · 03 Assumption
Pericardial Effusions, %
Rate of Pericardial effusions
LAA (within 7 days) 2 · 07 1 · 50 2 · 40 [5, 14]
Success implantation, %
Rate of LAA device implanted after discontinuing warfarin 0.868 0.8342 0.9018 [18]
Hospitalization
Annual rate of Hospitalization, %
Warfarin 20 · 80 15 · 5 26 · 10 [3]
Dabigatran, 110 mg 19 · 40 13 · 49 25 · 32 [3]
Dabigatran, 150 mg 20 · 20 19 · 94 20 · 46 [3]
Apixaban 20 · 80 15 · 50 26 · 10 Assumed equal to Wafarin
Rivaroxaban 20 · 80 15 · 50 26 · 10 Assumed equal to Wafarin
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Hemorrhage
Hemorrhages were classified into 4 categories: minor,
major, ICH and fatal (Table 1). The annual rates of ICH
were 0 · 2 %, 0 · 4 %, 0 · 75 %, 0 · 23 %, 0 · 3 %, 0 · 33 %,
and 0 · 5 % for ASA alone, clopidogrel plus ASA, war-
farin, dabigatran 110 mg, dabigatran 150 mg, apixaban,
and rivaroxaban, respectively [2–4, 13, 15]. The rate of
ICH after LAAO was 0 · 37 % for the first year and 0 · 2 %
for the second year onwards. A pro-rata method was used
to estimate the event rates for LAAO based on patients’
duration of taking ASA, clopidogrel plus ASA, or warfarin
therapy (Table 1). We assumed the bleeding rate in the
first year after LAAO was lower than warfarin or clopido-
grel plus ASA since patients were treated with warfarin
for only 45 days followed by clopidogrel plus ASA for
180 days. Bleeding rate from the second year onwards was
assumed to be the same as ASA alone [5, 12].
Myocardial infarction
The annual rates of MI was 0 · 9 % for ASA, 0 · 7 % for
clopidogrel plus ASA, 0 · 78 % for warfarin, 0 · 82 % for
dabigatran 110 mg, 0 · 81 % for dabigatran 150 mg, 0 · 53 %
for apixaban, and 0 · 91 % for rivaroxaban [2–4, 13, 19]. We
assumed the rate of MI in the first year after LAAO was
lower than warfarin or clopidogrel plus ASA since patients
were treated with warfarin for only 45 days followed by clo-
pidogrel plus ASA for 180 days. The rate of MI from the
second year onwards was assumed to be the same as ASA
alone [5, 12].
Pericardial effusions
The rate of serious pericardial effusions was 2 · 07 % for
patients who received LAAO within 7 days based on the
PROTECT-AF and PREVAIL studies [5, 14].
Success rate of LAA occlusion
LAAO success was defined when anticoagulation could
be discontinued after implantation of LAAO device.
According to published data, the success rate of LAAO
was 86.8 % and others were under warfarin therapy in
the LAAO strategy [18].
Hospitalization
The rates of hospitalization may be occurred after
patients with moderate to severe stroke or pericardial
effusions which were obtained from the RE-LY [3], PRO-
TECT-AF [5], and the Birmingham Atrial Fibrillation
Treatment of the Aged (BAFTA) trial [20]. The
hospitalization rates for warfarin, dabigatran 110 mg, dabi-
gatran 150 mg, and LAAO device were 20 · 8 %, 20 · 2 %,
19 · 4 %, and 1 · 08 %, respectively. The rates of apixaban
and rivaroxaban were assumed to be the same as warfarin
(Table 1).
Table 1 Clinical inputs for base-case value and ranges in decision analytic model (Continued)
LAA 1 · 08 0 · 00 5 · 00 [5]
Relative Risk of Hospitalization, %
Warfarin vs. aspirin 1 · 22 0 · 64 2 · 36 [20]
Warfarin vs. clopidogrel plus aspirin 1 · 22 0 · 64 2 · 36 Assumed equal to Aspirin
Death
Death from vascular cause, %
Aspirin alone 4 · 70 4 · 48 4 · 92 [2]
Clopidogrel plus aspirin 4 · 70 4 · 18 5 · 26 [2]
Warfarin 2 · 10 1 · 71 2 · 69 [3, 4, 13]
Dabigatran, 110 mg 2 · 43 2 · 23 2 · 63 [3]
Dabigatran, 150 mg 2 · 28 2 · 03 2 · 53 [3]
Apixaban 1 · 80 1 · 54 2 · 10 [13]
All-cause mortality, %
Aspirin alone 6 · 60 5 · 53 7 · 67 [2]
Clopidogrel plus aspirin 6 · 40 5 · 87 7 · 13 [2]
Warfarin 2 · 89 0 · 50 4 · 13 [3]
Dabigatran, 110 mg 3 · 75 3 · 51 3 · 99 [3]
Dabigatran, 150 mg 3 · 64 3 · 28 4 · 00 [3]
Apixaban 3 · 52 3 · 15 3 · 90 [13]
Rivaroxaban 4.50 4.01 4.99 [4]
LAA 3.20 1.56 4.84 [21]
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Table 2 Health utilities and costs for base-case value and ranges in decision analytic model
Variable Base-Case Range References
Quality of life
Mean utility score
Aspirin alone 0 · 998 0 · 994 1 · 0 [10]
Clopidogrel plus aspirin 0 · 998 0 · 994 1 · 0 Assumed equal to Aspirin
Warfarin 0 · 987 0 · 953 1 · 0 [10]
Dabigatran 0 · 994 0 · 975 1 · 0 [17, 19]
Apixaban 0 · 994 0 · 975 1 · 0 Assumed equal to Dabigatran
Rivaroxaban 0 · 994 0 · 975 1 · 0 Assumed equal to Dabigatran
LAA 0 · 998 0 · 994 1 · 0 Assumed equal to Aspirin
Stroke
Mild neurologic sequelae 0 · 75 0 · 75 1 · 0 [10]
Moderate to severe neurologic
sequelae 0 · 39 0 · 39 1 · 0 [10]
Myocardial infarction 0 · 84 0 · 84 1 · 0 [23]
Hemorrhage
Minor hemorrhage 0 · 8 0 · 5 0 · 99 [15–17, 24]
Major hemorrhage 0 · 8 0 · 5 0 · 99 [15–17, 24]
Cost, US$
Annual cost of medication or device
Aspirin alone 10 · 0 5 · 0 15 · 0 [10]
Clopidogrel plus aspirin 1,857 · 0 365 · 0 2,785.5 [10]
Warfarin 180 · 0 60 · 0 270 · 0 [10]
Dabigatran 3,240 · 0 2,500 · 0 4,860 [10]
Apixaban 3,920 · 1 1960 · 1 5,880 · 2 [25]
Rivaroxaban 2,660 · 9 1,330 · 4 3,991 · 3 [25]
LAA 22,500 20,384 24,614 [26], Assumption
Cost of INR +minimal established patient visit 26 · 0 10 · 0 39.0 [10]
Short term cost of neurological event
Moderate to severe ischemic neurological event 14,680 · 0 6,000 · 0 25,000 · 0 [10]
Minor ischemic neurological event 9,200 · 0 3,500 · 0 15,000 · 0 [10]
TIA 7,500 · 0 3,000 · 0 12,000 · 0 [10]
ICH 38,500 · 0 15,000 · 0 60,000 · 0 [10]
Long term cost of neurological event
Moderate to severe ischemic neurological event 5,400 · 0 2,000 · 0 8,000 · 0 [10]
Minor ischemic neurological event 2,470 · 0 1,000 · 0 4,000v0 [10]
TIA 5,700 · 0 2,000 · 0 9,000 · 0 [10]
ICH 7,200 · 0 3,000 · 0 12,000 · 0 [10]
Other costs, US$ [10]
Transesophageal echocardiogram 334.0 167.0 501.0 [27]
Major bleeding without residua 4,400 · 0 1,500 · 0 6,000 · 0 [10]
Minor bleeding 69 · 0 34 · 5 200 · 0 [10]
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Death
The rates of cardiovascular and all-cause mortality for ASA
alone, clopidogrel plus ASA, warfarin, dabigatran 110 mg,
dabigatran 150 mg and apixaban were 4 · 7 % and 6 · 6 %,
4 · 7 % and 6 · 4 %, 2 · 1 % and 2 · 89 %, 2 · 43 % and 3 · 75 %,
2 · 28 % and 3 · 64 %, 1 · 8 % and 3 · 52 %, respectively [2–4,
13]. The all-cause mortality rates of rivaroxaban and LAAO
were 4.5 % and 3.2 % input the model [4, 21].
Quality of life
Health utilities were obtained from published data (Table 2).
The mean utility score was 0 · 998 for ASA, 0 · 987 for
warfarin [10]. The utility score for dabigatran of 0 · 994 was
based on estimation of previous studies for another direct
thrombin inhibitor, ximelagatran [15, 17, 22]. The utility
score for dual anti-platelet therapy with clopidogrel plus
ASA, and LAAO were assumed to be the same as ASA;
otherwise, the utility score for apixaban and rivaroxaban
were assumed to be the same as dabigatran in this study.
The mean utility score was 0 · 75 for mild stroke, 0 · 39
for moderate to severe stroke [10]. The utility score of
MI (0 · 84) was derived from a nationally representative
EQ-5D index scores for a study of chronic conditions in
the US [23]. The utility score for minor or major
hemorrhage was 0.8 [15–17, 24].
Cost measurement
Direct inpatient and outpatient medical costs were esti-
mated from a healthcare provider perspective (Table 2).
The cost data for the base-case and their ranges were
based on a two cost-effectiveness studies of stroke pre-
vention in AF patients [10, 25]. These costs included the
costs of anti-thrombotic therapy, hemorrhage, neuro-
logical ischemia, dyspepsia, or MI. The estimated cost
for LAAO procedure was based on the mean charge of
US$14,614 for LAA implantation procedure [26] plus
the cost of the LAA occluding device of US$7,885
(US$5,770-US$10,000) that led to the total cost in our
analysis as US$22,500. Transesophageal echocardiog-
raphy (TEE) was performed at the time of LAA device
implantation and at 45 days, thus the cost of TEE was
US$334 [27].
Sensitivity analysis
One-way sensitivity analysis was performed by varying
CHADS2 score, HAS-BLED score, time horizons, and
different costs of LAA occlusion for all treatment
strategies in this study. The stroke rate for patients with
AF was increased by CHADS2 score (0–6), which were
assumed to be 0 · 8 %, 2 · 2 %, 4 · 5 %, 8 · 6 %, 10 · 9 %,
12.3 % and 13.7 %, respectively [18]. The hemorrhage
rates were increased by HAS-BLED score (0–5 score),
which were assumed to be 1 · 13 %, 1 · 02 %, 1 · 88 %, 3 ·
74 %, 8 · 7 %, and 12 · 5 %, respectively [8]. Time horizon
was varied from 20 to 5, 10, and 15 years to assess
shorter-term cost-effectiveness from a start-age of
65 years. Sensitivity analysis was also performed with
lower and higher costs of LAAO. One-way sensitivity
analysis illustrated with tornado diagram was used to as-
sess parameter uncertainty and estimate which parame-
ters had the greatest impact in the model. The
parameter was identified as sensitive when either the
range was the widest or the ICER value was greater than
a threshold of US$50,000. The parameters in warfarin
and LAAO strategies were pooled from two or more tri-
als (Tables 1 and 2).
Probabilistic sensitivity analysis (PSA) using 10,000
Monte Carlo simulations was conducted to assess par-
ameter uncertainty. The ranges of all parameters were
obtained from published studies and calculating formula
of 95 % confidence interval (Tables 1 and 2). A beta distri-
bution was used for those parameters between 0 and 1.
Cost data were non-negative quantitative data thus apply-
ing a gamma distribution.
Results
Base-case analysis
Under base-case conditions, LAAO was considered cost-
effective compared with the 7 alternative pharmacological
stroke prevention strategies for a hypothetical cohort of 65-
year-old patient with non-valvular AF (Table 3 and Fig. 1).
In descending sequence, the total costs of all strategies were
apixaban ($53,315), rivaroxaban ($51,064), dabigatran
150 mg ($43,946), dabigatran 110 mg ($42,712), LAAO
($37,789), warfarin ($28,090), clopidogrel plus ASA
($26,287) and ASA alone ($12,877), respectively. LAAO
was associated with the greatest QALYs (10.99 QALYs),
followed by rivaroxaban (9.86 QALYs), warfarin (9.45
QALYs), apixaban (9 · 40 QALYs), dabigatran 150 mg (9 · 0
QALYs), dabigatran 110 mg (8.76 QALYs), clopidogrel plus
ASA (6 · 29 QALYs) and ASA alone (6 · 12 QALYs).
The ICER per QALY gained for LAA occlusion com-
pared with ASA alone, clopidogrel plus ASA and war-
farin were $5,115, $2,447 and $6,298, respectively.
Table 2 Health utilities and costs for base-case value and ranges in decision analytic model (Continued)
Cost of non-stroke, non-hemorrhage death 10,000 · 0 5,000 · 0 20,000 · 0 [10]
MI 17,000 · 0 5,000 · 0 50,000 · 0 [10]
Hospitalization for stroke 80,964 · 0 40,482 · 0 121,446 · 0 Assumption
Hospitalization for pericardial effusions 73,770 · 0 36,885 · 0 110,655 · 0 Assumption
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Aspirin $12,877 6 · 12 $2,104 — Dominateda Dominateda Dominateda Dominateda Dominateda Dominateda Dominateda —
Clopidogrel
plus aspirin
$26,287 6 · 29 $4,179 $78,882 — Dominateda Dominateda Dominateda Dominateda Dominateda Dominateda Extended
dominance
Warfarin $28,090 9 · 45 $2,972 $4,568 $571 — Dominateda Dominatedb Dominatedb Dominateda Dominatedb $571
LAA
Occlusion
$37,789 10.99 $3,438 $5,115 $2,447 $6,298 — Dominatedb Dominatedb Dominatedb Dominatedb $6,298
Dabigatran
110 mg
$42,712 8.76 $4,876 $11,301 $6,650 Dominatedc Dominatedc — Dominateda Dominateda Dominateda Dominateda
Dabigatran
150 mg
$43,946 9.00 $4,883 $10,788 $6,516 Dominatedc Dominatedc $5,142 — Dominateda Dominateda Dominateda
Rivaroxaban $51,064 9.86 $5,179 $10,210 $6,940 $56,034 Dominatedc $7,593 $8,277 — Dominateda Dominateda
Apixaban $53,315 9.40 $5,672 $12,329 $8,691 Dominatedc Dominatedc $16,567 $23,423 Dominatedc — Dominateda
Abbreviations: LAA left atrial appendage, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year, Extended dominance the alternative has a higher ICER than a more effective comparator
aLess costly and less effective strategy
bLess costly but more effective strategy













LAAO was dominant (i.e. less costly but more effective)
compared to dabigatran 110 mg, dabigatran 150 mg,
apixaban, and rivaroxaban.
Sensitivity analysis
Sensitivity analysis demonstrated that LAAO remained
cost-effective compared with other strategies when stroke
risk was varied from CHADS2 score 0 to 6 (Table 4). In
particular, dabigatran 110 mg, dabigatran 150 mg,
apixaban and rivaroxaban were dominated by LAAO.
When hemorrhage rate was varied by HAS-BLED score
from 0 to 5 for anticoagulant drugs in the simulation
model, LAAO remained cost-effective compared with
each strategy. Varying the time horizon from 20 to 15, 10
and 5 years did not affect the cost-effectiveness of LAAO
against all other treatment strategies except for warfarin
(ICER: US$74,422) with a short 5 years time horizon. In
tornado diagram, the results demonstrated the parameters
with greatest impact were all-cause mortality of warfarin
(−$32,048–$12,994) and all-cause mortality of LAAO
($3,631–$24,716), respectively (Fig. 2). PSA results dem-
onstrated that the probability of LAAO strategy was the
most cost-effective compared with other 7 strategies in
86.24 % of 10,000 Monte Carlo simulations at the thresh-
old of US$50,000/QALY (Fig. 3).
Discussion
Previous study has demonstrated the cost-effectiveness
of LAAO, dabigatran and warfarin in the management
of NVAF [28]. This was the first comprehensive analysis
to compare the cost-effectiveness between seven
pharmacological strategies including newer oral antico-
agulants and transcatheter LAA occlusion for stroke
prevention in NVAF patients. We demonstrated that
LAAO was associated with the highest QALYs gained
and the lowest ICER per QALY gained compared to 7
other pharmacological regimens in the prevention of
AF-related stroke. Sensitivity analysis also demonstrated
that LAAO remained cost-effective compared with all 7
alternative strategies across the spectrum of stroke risks,
bleeding risk and time horizon.
Atrial fibrillation is a growing problem in an aging so-
ciety. It causes >50 000 strokes and $12 billion in med-
ical expenditure each year in United States. Warfarin
used to be the standard of care in preventing stroke but
it is difficult to be used conveniently and safely [29].
Fig. 1 Shows the result of ICER values in comparison of the next-best strategy, and the black line connected from acetylsalicylic acid (ASA) to LAA
occlusion as the cost-effectiveness frontier. The effectiveness is defined as the change of quality adjusted life year (QALY) gained. The cost-effectiveness
frontier ran from ASA to warfarin to LAA occlusion and its slope increased when moving from the least costly/least effective alternative (ASA) towards
the most costly/most effective alternative (LAA occlusion). Clopidogrel plus ASA was an extended dominance* strategy. LAA occlusion is the next
more-effective strategy comparing to warfarin, ICER per QALY gained was US$6,298. Dabigatran 110 mg, dabigatran 150 mg, rivaroxaban, and apixaban
were dominated by LAA occlusion because those four alternatives were less effective but more costly than LAA occlusion. *Extended dominance: This
refers to the observation when the ICER value for a given strategy is higher than that of the next, more effective, alternative. Clopidogrel plus ASA had
a higher ICER value than a more effective alternative (warfarin)
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Table 4 Sensitivity analysis of total Costs, total QALYs, and ICERs of LAA occlusion compared with each strategy by varying CHADS2 score, HAS-BLED score, time horizons, and
LAA occlusion costs
Aspirin Clopidogrel + Aspirin Warfarin Dabigatran 110 mg Dabigatran 150 mg Apixaban Rivaroxaban LAAO
CHADS2 Score Cost QALY Cost QALY Cost QALY Cost QALY Cost QALY Cost QALY Cost QALY Cost QALY
0 (0 · 8 %) $10,117 6 · 36 $24,998 6 · 42 $27,027 9 · 54 $41,569 8 · 87 $43,685 9 · 02 $52,949 9 · 44 $50,966 9.98 $37,567 11.01
1 (2 · 2 %) $12,073 6 · 19 $26,627 6 · 25 $30,565 9 · 25 $44,469 8 · 60 $46,627 8 · 75 $55,868 9 · 15 $54,107 9.67 $40,971 10.65
2 (4 · 5 %) $15,048 5.93 $29,098 5 · 99 $35,853 8 · 81 $48,807 8 · 20 $51,021 8 · 34 $60,207 8 · 71 $58,766 9.19 $46,033 10.11
3 (8 · 6 %) $19,710 5 · 52 $32,949 5 · 57 $43,894 8 · 11 $55,412 7 · 57 $57,698 7 · 69 $66,749 8 · 01 $65,765 8.44 $53,661 9.25
4 (10 · 9 %) $22,017 5 · 31 $34,846 5 · 36 $47,753 7 · 76 $58,587 7 · 25 $60,899 7 · 37 $69,859 7 · 67 $69,080 8.07 $57,288 8.83
5 (12.3 %) $23,327 5.19 $35,919 5.24 $49,905 7.57 $60,359 7.07 $62,684 7.18 $71,586 7.47 $70,915 7.86 $59,299 8.59
6 (13.7 %) $24,571 5.08 $36,937 5.13 $51,922 7.38 $62,021 6.90 $64,357 7.01 $73,198 7.28 $72,626 7.66 $61,177 8.36
ICER, US$ LAAO
vs. each strategy
Score 0: $5,903 Score 0: $2,738 Score 0: $7,170
Score 1: $6,479 Score 1: $3,260 Score 1: $7,433
Score 2: $7,413 Score 2: $4,110 Score 2: $7,831
Score 3: $9,102 Score 3: $5,628 Score 3: $8,568 Dominated Dominated Dominated Dominated —
Score 4: $10,020 Score 4: $6,467 Score 4: $8,911
Score 5: $10,580 Score 5: $6,979 Score 5: $9,210
Score 6: $11,160 Score 6: $7,505 Score 6: $9,444
HAS-BLED Score Cost QALY Cost QALY Cost QALY Cost QALY Cost QALY Cost QALY Cost QALY Cost QALY
0 (1.13 %) $12,877 6 · 12 $26,287 6 · 29 $36,827 9 · 40 $62,062 8 · 64 $61,719 8 · 88 $72,551 9 · 30 $69,642 9.78 $38,858 10.98
1 (1.08 %) $12,877 6 · 12 $26,287 6 · 29 $34,333 9 · 42 $59,791 8 · 66 $59,450 8 · 89 $69,999 9 · 31 $66,679 9.79 $38,552 10.99
2 (1.88 %) $12,877 6 · 12 $26,287 6 · 29 $53,095 9 · 31 $76,902 8 · 55 $76,534 8 · 77 $89,207 9 · 21 $88,969 9.69 $40,851 10.97
3 (3.74 %) $12,877 6 · 12 $26,287 6 · 29 $88,462 9 · 09 $109,305 8 · 35 $108,814 8 · 55 $125,481 9 · 02 $130,998 9.50 $45,208 10.95
4 (8.7 %) $12,877 6 · 12 $26,287 6.29 $156,713 8 · 67 $172,530 7 · 94 $171,469 8 · 09 $195,786 8 · 65 $212,146 9.13 $53,713 10.89
5 (12.5 %) $12,877 6 · 12 $26,287 6.29 $191,794 8 · 45 $205,517 7 · 73 $203,929 7 · 85 $232,133 8 · 45 $253,872 8.94 $58,139 10.87
ICER, US$ LAAO
vs. each strategy
Score 0: $5,346 Score 0: $2,680 Score 0: $1,285
Score 1: $5,272 Score 1: $2,610 Score 1: $2,687
Score 2: $5,768 Score 2: $3,112 Score 2: Dominated
Score 3: $6,694 Score 3: $4,060 Score 3: Dominated Dominated Dominated Dominated Dominated —
Score 4: $8,561 Score 4: $5,962 Score 4: Dominated
Score 5: $9,529 Score 5: $6,955 Score 5: Dominated
Time horizon Cost QALY Cost QALY Cost QALY Cost QALY Cost QALY Cost QALY Cost QALY Cost QALY
5 years $6,100 3 · 47 $12,529 3 · 50 $6,898 4 · 02 $17,516 3 · 94 $17,374 3 · 97 $20,356 4 · 03 $17,040 4.08 $24,015 4.25













Table 4 Sensitivity analysis of total Costs, total QALYs, and ICERs of LAA occlusion compared with each strategy by varying CHADS2 score, HAS-BLED score, time horizons, and
LAA occlusion costs (Continued)
15 years $11,801 5 · 78 $24,048 5 · 92 $22,111 8 · 34 $37,471 7 · 85 $38,190 8 · 02 $45,834 8 · 31 $42,397 8.63 $33,699 9.44
ICER, US$ LAAO
vs. each strategy
0 5 years: $22,968 0 5 years: $15,315 5 years: $74,422 5 years: $20,965 05 years: $23,718 5 years: $16,632 5 years: $41,029
10 years: $8,666 10 years: $4,217 10 years: $21,769 10 years: Dominated 10 years: Dominated 10 years: Dominated 10 years: Dominated —
15 years: $5,983 15 years: $2,742 15 years: $10,535 15 years: Dominated 15 years: Dominated 15 years: Dominated 15 years: Dominated
LAAO costs Cost QALY Cost QALY Cost QALY Cost QALY Cost QALY Cost QALY Cost QALY Cost QALY
Low cost ($20,384) $12,877 6.12 $26,287 6.29 $28,090 9.45 $42,712 8.76 $43,946 9.00 $53,315 9.40 $51,064 9.86 $36,731 10.99
Base-case ($22,500) $12,877 6.12 $26,287 6.29 $28,090 9.45 $42,712 8.76 $43,946 9.00 $53,315 9.40 $51,064 9.86 $37,789 10.99
High cost ($24,614) $12,877 6.12 $26,287 6.29 $28,090 9.45 $42,712 8.76 $43,946 9.00 $53,315 9.40 $51,064 9.86 $38,846 10.99
ICER, US$ LAAO
vs. each strategy
Low cost: $4,898 Low cost: $2,222 Low cost: $5,611
Base-case: $5,115 Base-case: $2,447 Base-case: $6,298 Dominated Dominated Dominated Dominated —
High cost: $5,332 High cost: $2,672 High cost: $6,984
Abbreviations: LAAO left atrial appendage occlusion, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year, CHADS2 congestive heart failure, hypertension, age > 75, diabetes mellitus, and previous
stroke/transient ischemic attack, HAS-BLED hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, Labile international normalized ratio, Elderly (>65 years), drugs/alcohol concomitantly,













Fig. 2 Shows the Tornado diagram with parameters having the greatest impact on the top. The gray dotted line was the ICER value (US$6,298)
of LAA occlusion compared to warfarin with base-case result. The all-cause mortalities of warfarin (variable range: 0.5 to 4.13 %) and LAA occlusion
(variable range: 1.8 to 2.7 %) had the greatest impact in the model. Even though the range of ICER values of the two parameters were not greater
than the threshold of US$50,000, both parameters could still affect the results in the model. The other parameters assessed were not sensitive to
the model’s outcomes
Fig. 3 Shows Cost-effectiveness Acceptability Curves (CEACs) for the probability that LAA occlusion strategy was the most cost-effective compared
with other 7 strategies for a range of willingness to pay threshold. Given a maximum acceptable ceiling ratio of US$50,000 per QALY gained,
the probability of cost-effectiveness for LAA occlusion strategy was 86.24 %
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NOACs may be comparable to warfarin in terms of clin-
ical efficacy but the benefit does not come without risk
of bleeding. Transcatheter LAAO potentially reduces
both risks of stroke and bleeding associated with long-
term anticoagulation and the 2012 European Society of
Cardiology Guidelines recommended such intervention
can be considered in patients with high stroke risk and
contraindications for oral anticoagulants [30]. A few
studies attempted to evaluate the cost-effectiveness of
these newer stroke preventive strategies. One key ana-
lysis based on the RE-LY study [3] showed the ICERs of
dabigatran 110 mg and 150 mg compared with warfarin
were US$16,147–115,129 and US$39,680–263,543, re-
spectively, which were much higher compared to the
ICER for LAAO in our current study. SM Singh, A
Micieli and HC Wijeysundera [8] demonstrated LAAO
was cost-effective as compared to dabigatran and war-
farin but they did not address the impact of other com-
monly used NOACs and the treatment duration on the
cost-effective performance of the device therapy [28]. In
current analysis, we demonstrated the superior cost-
effectiveness of the device compared to other NOACs,
which is independent of stroke risk (CHADS2 score),
bleeding risk (HAS-BLED score) and treatment duration
(i.e. device strategy was cost-effective even at 5 year
follow-up). In particular, LAAO was considered cost-
effective comparing to all alternative strategies when
HAS-BLED score and CHADS2 score were varied. Con-
sidering most adverse events occur during and shortly
after device implantation [5, 20], while events with oral
anticoagulants develop continuously over time, our find-
ings may provide additional insights in selecting specific
therapy for individual patient groups.
Three endovascular LAA occluding devices have been
widely used in humans and many other new devices are
under pre-clinical evaluation [31]. The PLAATO device
was the oldest with reported favorable clinical results
up to 5 years but the device has been withdrawn from
the market because of financial considerations [32].
PROTECT-AF trial [5] showed the WATCHMAN de-
vice was non-inferior to warfarin in reducing ischemic
stroke in AF patients with CHADS2 score of ≥1 and the
device arm was associated with less hemorrhagic
stroke. Early registry results with Amplatzer Cardiac
Plug (St Jude Medical Inc, US), consistently reported a
high implantation success rate >95 %, implying its wide
applicability to AF patients [6, 33]. The longest follow-
up data were also shown to demonstrate the promising
results with Amplatzer device in AF patients for stroke
prevention [33]. While the device therapy addresses
both the concerns of inconvenience (no issue with drug
interaction, blood monitoring and compliance) and
safety (bleeding) associated with long term oral anti-
coagulant usage, it also has shortcomings in particular
procedural-related complications [5, 6, 12, 14] and the
risks of having incomplete LAAO and thrombus forma-
tion on the device during long-term follow up. The
costs of managing these events needed to be studied es-
pecially when the device strategy has been widely
adopted in in-experienced centers.
Limitations
There are a number of limitations of the current study.
Firstly, there was no directly comparative trial between
LAAO and oral anticoagulation. Secondly, the base-case
values of the current model simulation were derived
from individual clinical trials from different countries
and healthcare systems with variable costs of manage-
ment. Thirdly, a number of base-case assumptions were
necessary when trial data were lacking. Fourthly, data
from randomized clinical trials could not be
generalizable to “real world” clinical practice. It should
also be noted that only direct medical cost was consid-
ered in the analysis. Fifthly, we assumed that warfarin
was discontinued after 45 days post LAAO although
some patients may require warfarin beyond 45 days
when TEE confirmed clots or device leak. Furthermore,
the long-term follow-up data for the newer LAAO de-
vices were obtained from a single study with 10-year fol-
low up of Amplatzer left atrial appendage occlusion [33],
it may add to model uncertainties and parameter uncer-
tainties in the results, however, sensitivity analyses dem-
onstrated the robustness of study results.
Conclusions
In conclusion, our Markov analytic model demonstrated
that transcatheter LAAO was cost-effective compared to
ASA alone, clopidogrel plus ASA, warfarin, dabigatran
110 mg, dabigatran 150 mg, rivaroxaban and apixaban
for stroke prevention in patients with NVAF.
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